Evaluation of the Activity of a Pharmacological "Anticellulitis" Product vs. a Reference Product on the Market

July 17, 2014 updated by: Derming SRL

Clinical and Instrumental Evaluation of the Activity of a Pharmacological "Anticellulitis" Product vs. a Reference Product on the Market: Comparison Within Subjects (Double Blind Study)

Aim of this study was to evaluate by clinical, morphometric and non invasive instrumental evaluations the activity of an "anticellulitis" cosmetic product vs a reference product of the market (comparison within subjects), applied once a day, for an uninterrupted period of 4 weeks, on 22 female healthy volunteers with low/moderate oedematous - fibrosclerotic lipodystrophy on the thighs.

It was also aim of the study to evaluate cosmetic acceptability by the volunteers and products efficacy and tolerance both by investigator and volunteers.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

22

Phase

  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • female volunteers
  • volunteers aged more than 18 years old
  • volunteers with low/moderate oedematous - fibrosclerotic lipodystrophy on the thighs
  • volunteers with no weight variation (± 1.5 kg) during the last month preceding the study inclusion
  • volunteers with regular menstrual cycle (28-32 days) or in menopause from at least 2 years
  • volunteers who are giving a written informed consent.

Exclusion Criteria:

  • pregnancy
  • lactation
  • smoke (admitted 10 cigarettes/day)
  • assumption of alcoholic drinks/wine/beer (admitted up to 125 ml for meal)
  • oral contraceptive/replacement therapy started less than 1 year ago
  • alimentary diet
  • change in the normal habits in the last month (unusual physical activity)
  • use of any product or weight-loss treatment (manual or instrumental massage) on skin test areas during the last month
  • use of any drug able to cause a weight body variation
  • presence of clinically important vascular disorders
  • insufficient adhesion to the study protocol and to the treatment
  • participation in a similar study during the previous month
  • dermatological disease
  • clinical and significant skin condition on the test area (e.g. lesions, scars, malformations)
  • suspect thyroid disfunction
  • thyroid disorders/diseases
  • other endocrine diseases as diabetes, metabolic disorders etc.
  • hepatic, renal or cardiac disorder
  • cancer
  • topical drugs or surgical procedure on the test areas during the previous 3 months
  • systemic corticosteroids
  • aspirin or non-steroid anti-inflammatory drugs (FANS)
  • diuretic drugs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: ANTICELLULITE GMG GIULIANI
Each included subject applied ANTICELLULITE GMG GIULIANI mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
Active Comparator: SOMATOLINE
Each included subject applied SOMATOLINE CREAM mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Morphometric evaluations: change from baseline (T2 and T4 vs. T0)
Time Frame: after 2 and 4 week-treatment
All the measures were performed in standard conditions at level of the thigh (III superior, III middle and inferior), thanks to a specific electro-optical system.
after 2 and 4 week-treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ultrasonographic evaluations: change from baseline (T2 and T4 vs. T0)
Time Frame: after 2 and 4 week-treatment
Ultrasonographic measurement of adipose panniculum thickness (mm) was performed at level of the external thigh (III superior) through the instrument Body Metrix™ BX 2000 (Genex).
after 2 and 4 week-treatment
Skin plastoelasticity: change from baseline (T2 and T4 vs. T0)
Time Frame: after 2 and 4 week-treatment

Skin elasticity was measured through the instrument Dermal Torque Meter (Dia-Stron Ltd., UK). This instrument is based on the principle of the torsion given to the skin surface by a probe made of two circles that adhere to the skin through shaped adhesive tapes. The instrument measures the torsion angle (θ) during the mechanical stimulus ("torque on") and after it has ceased ("torque off"). For each of the considered curves it was measured the cutaneous rotational ratio relative to defined measured times, obtaining the parameters listed below:

Ue: immediate extensibility ("torque on" at 0.2 sec.) Uf: final extensibility ("torque on" at 9 sec.) Uv: viscoelasticity Ur: immediate elastic recovery ("torque off" at 0.2 sec.)

after 2 and 4 week-treatment
Tissue dielectric constant of deep skin layers: change from baseline (T2 and T4 vs. T0)
Time Frame: after 2 and 4 week-treatment
Tissue dielectric constant of deep skin layers misures non-invasively the dielectric constant of the subcutaneous fat; it is a dimensionless physical quantity and it is directly proportional to the water content in the measured tissue. The used probe corresponds to an effective measurement depth of 5 mm; the measure were performed at level of the external thigh (III superior).
after 2 and 4 week-treatment
Optical densitometry: change from baseline (T2 and T4 vs. T0)
Time Frame: after 2 and 4 week-treatment
The measurement of the skin erythema at level of the internal area of the knee was performed by the use of an optical densitometer (X-RITE 404) allowing to quantify, on a logarithmic scale, total reflected optical density (visual=V) and the values of primary subtractive colours of reflected light: cyan(=C), magenta(=M) and yellow(=Y). Calculation of erythema index was done as follows: E.I.=logRmagenta-logRcyan, where R represents the reflectance.
after 2 and 4 week-treatment
Thermography evaluation: change from baseline (T2 and T4 vs. T0)
Time Frame: after 2 and 4 week-treatment

Contact thermography permits visualizing, through colors, the temperatures of the areas being examined by using encapsulated liquid crystals plates; it allows to detect information about cutaneous microcirculation in normal conditions, after functional stimuli or vasoactive treatments: skin temperature grows in case of vasodilatation, increase of blood vessels, increase local metabolism and reduced in case of vasoconstriction, pathological decrease of blood vessels, decrease of local metabolism, oedema and increase of adipose tissue. A characteristic thermography aspect of legs' oedematous - fibrosclerotic lipodystrophy is represented by the typical leopard skin with large hypothermic zones. Panniculopatia evaluation follows next classification:

0 = uniform hyperthermal image

  1. = shaded spots thermal image (hyperthermal images)
  2. = leopard spots (numerous hyperthermal images)
  3. = hypothermal black holes
  4. = uniform hypothermal image
after 2 and 4 week-treatment
Clinical evaluations: change from baseline (T2 and T4 vs. T0)
Time Frame: after 2 and 4 week-treatment

Performed at level of the III superior, of the III middle and inferior of the thigh:

  • cellulitis visual aspect (according to a reference photographic scale) no cellulitis 0 slight dimpling on skin surface 1 dimpling and skin depressions 2 dimpling and depressed striations 3 nodules and depressed striations 4
  • cellulitis aspect to pinching ( according to a reference photographic scale) no cellulitis 0 slight dimpling on skin surface 1 dimpling and skin depressions 2 dimpling and depressed striations 3 nodules and depressed striations 4
  • pain at pinching absent 0 slight 1 medium 2 consistent 3 very consistent 4
  • firmness (internal thigh) very poor 0 poor 1 medium 2 good 3 very good 4
  • smoothness very poor 0 poor 1 medium 2 good 3 very good 4
after 2 and 4 week-treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2013

Primary Completion (Actual)

October 1, 2013

Study Completion (Actual)

October 1, 2013

Study Registration Dates

First Submitted

July 10, 2014

First Submitted That Met QC Criteria

July 17, 2014

First Posted (Estimate)

July 21, 2014

Study Record Updates

Last Update Posted (Estimate)

July 21, 2014

Last Update Submitted That Met QC Criteria

July 17, 2014

Last Verified

July 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • E1513

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream

3
Subscribe